Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Income from Continuing Operations (2017 - 2025)

Cue Biopharma (CUE) has disclosed Income from Continuing Operations for 9 consecutive years, with 23207000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 1.73% to 23207000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4732000.0 through Dec 2025, up 31.6% year-over-year, with the annual reading at 5174000.0 for FY2025, 25.22% up from the prior year.
  • Income from Continuing Operations hit 23207000.0 in Q4 2025 for Cue Biopharma, up from 7373000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 23616000.0 in Q4 2024 to a low of 14255000.0 in Q1 2022.
  • Historically, Income from Continuing Operations has averaged 7865308.75 across 5 years, with a median of 11530500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 80.42% in 2022 and later surged 282.69% in 2024.
  • Year by year, Income from Continuing Operations stood at 7889175.0 in 2021, then crashed by 80.42% to 14234000.0 in 2022, then rose by 9.18% to 12927000.0 in 2023, then soared by 282.69% to 23616000.0 in 2024, then decreased by 1.73% to 23207000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CUE at 23207000.0 in Q4 2025, 7373000.0 in Q3 2025, and 8437000.0 in Q2 2025.